Plasma levels of the A subunit of factor XIII in patients undergoing off-pump coronary artery bypass surgery

Słomka, Artur; Korbal, Piotr; Piekuś, Aleksandra; Pawliszak, Wojciech; Anisimowicz, Lech; Żekanowska, Ewa

doi:10.20452/pamw.4076

Cited by 4 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in inflammation, there is a reduction in the number of platelets that contain factor XIII-A. However, thromboembolic stroke is not a simple inflammatory condition, and it should be noted that most papers aimed at investigating the correlation between factor XIII-A and CRP in thromboembolic conditions have not shown such a correlation [ 14 , 24 , 25 ]. The issue certainly requires further research.…”

Section: Discussionmentioning

confidence: 99%

The Usefulness of Factor XIII Concentration Assessment in Patients in the Acute Phase of Ischaemic Stroke Treated with Thrombolysis

Wiszniewska,

Włodarczyk,

Sury

et al. 2024

Neurology International

Self Cite

View full text Add to dashboard Cite

Background and Aims: In recent years, there has been a growing interest in factor XIII in ischaemic stroke. The study’s main aim was to assess the usefulness of factor XIII concentration determination in patients with acute ischaemic stroke (AIS) treated with thrombolysis with recombinant tissue plasminogen activator (t-PA). Methods: The study was conducted in two groups of 84 patients with AIS: group I—with thrombolytic therapy and group II—without thrombolysis. A physical examination, neurological status (using the National Institutes of Health Stroke Scale, NIHSS), daily patients’ activities measured with the Barthel Index and Modified Rankin Scale (mRS), and blood parameters were conducted on day 1 and day 7. The following parameters were assessed: highly sensitive C-reaction protein (CRP), fibrinogen, D-dimers (DD), neutrophil–lymphocyte ratio (NLR index), and the concentration of factor XIII-A. Results: In group I, the concentration of XIII-A decreased significantly between day 1 and 7 (p < 0.001). In group I, the concentration of XIII-A on day 7 in Total Anterior Circulation Infarct (TACI) was significantly lower than in non-TACI stroke. XIII-A concentration in group I was significantly lower in patients < 31 points with Acute Stroke Registry and Analysis of Lausanne (ASTRAL). A greater decrease in XIII-A between the first sampling on day 1 and the second sampling on day 7 was associated with a worse patient neurological state in group I. Conclusions: In patients with AIS treated with t-PA, factor XIII concentrations decrease in the acute phase of stroke, and the largest decrease occurs in the TACI stroke. Determination of factor XIII concentration in patients with AIS can be used in clinical practice as an additional parameter supporting the assessment of stroke severity and may play a role in the prognosis; lower factor XIII-A activity may be a predictor of a worse prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

The Usefulness of Factor XIII Concentration Assessment in Patients in the Acute Phase of Ischaemic Stroke Treated with Thrombolysis

Wiszniewska,

Włodarczyk,

Sury

et al. 2024

Neurology International

Self Cite

View full text Add to dashboard Cite

show abstract

“…CHD, one of the leading causes of death in the world, is a complex metabolic disorder due to genetic and environmental interactions. [21–23] Metabolomics, a powerful technical system that studies the entire metabolic pathway of a particular biological system. This technology has been increasingly used to identify metabolic biomarkers and improve clinical diagnosis and treatment of diseases.…”

Section: Discussionmentioning

confidence: 99%

Targeted metabolomic analysis of plasma metabolites in patients with coronary heart disease in southern China

et al. 2019

View full text Add to dashboard Cite

Coronary heart disease (CHD), one of the leading causes of death in the world, is a complex metabolic disorder due to genetic and environmental interactions. The potential mechanisms and diagnostic biomarkers for different types of coronary heart disease remain unclear. Metabolomics is increasingly considered to be a promising technology with the potential to identify metabolomic features in an attempt to distinguish the different stages of CHD. We aimed to investigate serum metabolite profiling between CHD patients and normal coronary artery (NCA) subjects and identify metabolic biomarkers associated with CHD progression in an ethnic Hakka population in southern China. Using a novel targeted metabolomics approach, we explored the metabolic characteristics of CHD patients. Blood samples from 302 patients with CHD and 59 NCA subjects were collected that analyses using targeted liquid-chromatography coupled with tandem mass spectrometry (LC-MS). A total of 361 blood samples were determined using targeted LC-MS. Plasma concentrations for trimetlylamine oxide (TMAO), choline, creatinine, and carnitine were significantly higher in patients with CHD compared to the NCA cohort. Further, we observed that the concentration of the 4 metabolites were higher than that of the NCA group in any group of CHD, which including acute myocardial infarction (AMI), unstable angina (UA), and stable angina (SA). In addition, the diagnostic model was constructed based on the metabolites identified and the ROC curve of the NCA subjects and CHD patients were performed. For choline and creatinine, the AUCs ranged from 0.720 to 0.733. For TMAO and carnitine, the AUCs ranged from 0.568 to 0.600. In conclusion, the current study illustrates the distribution of 4 metabolites between CHD patients and NCA subjects. Metabolomics analysis may yield novel predictive biomarkers that will potentially provide value for clinical diagnosis of CHD.

show abstract

“…[3] AMI is typically caused by activation of platelet aggregation at the site of a ruptured or eroded atherosclerotic plaque. [4,5] It is well recognized that age, sex, dyslipidemia, atherosclerosis, hypertension, smoking and diabetes are significantly associated with the risk of AMI. [6–8] Although the relationship between risk factors and AMI has been extensively researched, however, the relation between these 2 remains controversial due to somewhat divergent of the results depending on different clinical subgroups of AMI.…”

Section: Introductionmentioning

confidence: 99%

Differential expression of circulating long non-coding RNAs in patients with acute myocardial infarction

et al. 2018

View full text Add to dashboard Cite

show abstract

Plasma levels of the A subunit of factor XIII in patients undergoing off-pump coronary artery bypass surgery

Cited by 4 publications

References 1 publication

The Usefulness of Factor XIII Concentration Assessment in Patients in the Acute Phase of Ischaemic Stroke Treated with Thrombolysis

The Usefulness of Factor XIII Concentration Assessment in Patients in the Acute Phase of Ischaemic Stroke Treated with Thrombolysis

Targeted metabolomic analysis of plasma metabolites in patients with coronary heart disease in southern China

Differential expression of circulating long non-coding RNAs in patients with acute myocardial infarction

Contact Info

Product

Resources

About